A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir Disoproxil Fumarate (MVC+TDF), or Tenofovir Disoproxil Fumarate + Emtricitabine (TDF+FTC) For Pre-Exposure Prophylaxis (PrEP) To Prevent HIV Transmission in At-Risk Men Who Have Sex With Men and in At-Risk Women.
Latest Information Update: 08 May 2024
Price :
$35 *
At a glance
- Drugs Maraviroc (Primary) ; Emtricitabine; Tenofovir disoproxil fumarate
- Indications HIV infections
- Focus Adverse reactions
- Acronyms NEXT-PrEP
- 16 Feb 2022 Results presented at the 29th Conference on Retroviruses and Opportunistic Infections
- 13 Nov 2021 Results of BMD sub study (n=397) published in the Journal of Antimicrobial Chemotherapy.
- 06 Apr 2021 Results for substudy of HPTN 069/ACTG A5305, assessing differences in colorectal tissue susceptibility to HIV infection between MSM and CGW both before and during antiretroviral dosing, published in the AIDS